EGFR and neoplasm: The prominent role of EGFR signalling in many tumour types has prompted the development of pharmacological inhibitors such as the anilinoquinazolines (gefitinib and erlotinib), which disrupt EGFR kinase activity by binding the ATP pocket within the catalytic kinase domain (Wakeling, 2002).